Main considerable factors for correct laboratory test interpretation under DOA treatment

被引：13

作者：

Mani H. ^{[1
]}

Lindhoff-Last E. ^{[1
]}

机构：

[1] Department of Internal Medicine, Division of Vascular Medicine and Hemostaseology, Johann Wolfgang Goethe-University Hospital, Frankfurt/Main

来源：

Thrombosis Journal | / 11卷 / 1期

关键词：

Thrombin; Prothrombin Time; Dabigatran; Rivaroxaban; Apixaban;

D O I：

10.1186/1477-9560-11-22

中图分类号：

学科分类号：

摘要：

Summary: To avoid misinterpretation and mismanagement clinicians should be aware of the interference of new direct oral anticoagulants (DOA) on coagulation assays. A variety of oral anticoagulants targeting specific coagulation factors has already entered the market, and new indications for DOA will be released each year over the next few years. Due to their heterogeneous mode of action and different pharmacokinetic profile each DOA will vary in its effects on coagulations assays, and it is of current importance to recognize these variable effects.In this summary the main considerable factors for correct laboratory test interpretation under DOA treatment are described. © 2013 Mani and Lindhoff-Last; licensee BioMed Central Ltd.

引用

共 16 条

[1]

Ageno W., Gallus A.S., Wittkowsky A., Et al., Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines, Chest, 141, 2 SUPPL., (2012)

[2]

Samama M.M., Guinet C., Le Flem L., Do new oral anticoagulants require laboratory monitoring? The clinician point of view, Thromb Res, 130, SUPPL. 1, (2012)

[3]

Lindhoff-Last E., Samama M.M., Ortel T.L., Et al., Assays for measuring rivaroxaban: their suitability and limitations, Ther Drug Monit, 32, 6, pp. 673-769, (2010)

[4]

Wienen W., Stassen J.M., Priepke H., Et al., In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, Thromb Haemost, 98, pp. 155-162, (2007)

[5]

Samama M.M., Martinoli J.L., LeFlem L., Et al., Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor, Thromb Haemost, 103, 4, pp. 815-825, (2010)

[6]

Lindahl T.L., Baghaei F., Blixter I.F., Et al., Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays, Thromb Haemost, 105, 2, pp. 371-378, (2011)

[7]

Mani H., Hesse C., Stratmann G., Lindhoff-Last E., Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time, Thromb Haemost, 106, 1, pp. 156-164, (2011)

[8]

Douxfils J., Mullier F., Robert S., Et al., Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate, Thromb Haemost, 107, 5, pp. 985-997, (2012)

[9]

van Ryn J., Stangier J., Haertter S., Et al., Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity, Thromb Haemost, 103, 6, pp. 1116-1127, (2010)

[10]

Mani H., Hesse C., Stratmann G., Lindhoff-Last E., Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions, Thromb Haemost, 109, 1, pp. 127-136, (2013)

← 1 2 →